Clinical Trials Summary for out of hours Important Reference

Lancashire Teaching Hospitals NHS Foundation Trust

Acronym study title	ERASCA - SEACRAFT-2
Study Details	A RANDOMIZED, OPEN-LABEL PHASE 3 STUDY IN PATIENTS WITH PREVIOUSLY TREATED UNRESECTABLE OR METASTATIC NRAS MUTANT CUTANEOUS MELANOMA COMPARING THE COMBINATION OF NAPORAFENIB + TRAMETINIB TO PHYSICIAN'S CHOICE OF THERAPY (DACARBAZINE, TEMOZOLOMIDE OR TRAMETINIB MONOTHERAPY) WITH A DOSE OPTIMIZATION LEAD-IN [SEACRAFT-2]
Principal Investigator PI Sub PI's	**PI –** Prof Ruth Board **Sub Investigator –** Dr Kellati Prasad
Research Nurse Team	**Research Nurse -** Carolyn Hatch **CTSO -** Bethany Webster
Drug therapy	**Stage 1 Arm A Naporafenib 400 mg BD + Trametinib 0.5 mg OD** **Arm B Naporafenib 400 mg BD + Trametenib 1mg OD** **Arm C Trametenib 2mg OD** **Stage 2 Naporafenib dose to be decided from stage 1 vs Trametenib 2mg** **28 day cycles**
	Please inform Research team on 01772 522801 if patient is admitted to hospital or develops toxicity.